AZN has done two acquisitions, OMTH and Pearl, in areas they said openly they would do a couple of months ago: cardiovascular/metabolic, respiratory, and oncology. Both are moderate sized acquisitions, with either inferior and/or late to the party drugs.
Market Data 
Markets 
AI
